Strategy
MSTR
MARA Holdings
MARA
Adobe
ADBE
4
Meta Platforms
META
5
Microsoft
MSFT
US Stock MarketDetailed Quotes
TRVI Trevi Therapeutics
- 6.610
- +0.020+0.30%
Trading Apr 29 12:35 ET
639.07MMarket Cap-14.06P/E (TTM)
6.740High6.430Low2.71MVolume6.540Open6.590Pre Close17.87MTurnover3.68%Turnover RatioLossP/E (Static)96.68MShares7.39052wk High6.41P/B486.93MFloat Cap2.30052wk Low--Dividend TTM73.67MShs Float10.620Historical High--Div YieldTTM4.70%Amplitude0.460Historical Low6.597Avg Price1Lot Size
About Trevi Therapeutics Company
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.
Company Profile
SymbolTRVI
Company NameTrevi Therapeutics
Listing DateMay 7, 2019
Issue Price10.00
Founded2011
CEOMs. Jennifer L. Good
MarketNASDAQ
Employees26
Fiscal Year Ends12-31
Address195 Church Street,16th floor
CityNew Haven
ProvinceConnecticut
CountryUnited States of America
Zip Code06510
Phone1-203-304-2499
Company Executives
- Name
- Position
- Salary
- Jennifer L. Good
- President, Chief Executive Officer and Director
- 1.69M
- Farrell Simon
- Chief Commercial Officer
- --
- Dr. Thomas R. Sciascia,M.D.
- Chief Scientific Officer
- 977.13K
- Dr. James V. Cassella,PhD
- Chief Development Officer
- 112.95K
- Lisa Delfini
- Chief Financial Officer
- --
- Christopher Galletta
- Controller and Principal Accounting Officer
- --
- Dr. David P. Meeker,M.D.
- Chairman of the Board
- 135.45K
- Anne M. Vanlent
- Independent Director
- 127.95K
- Michael T. Heffernan, R.Ph.
- Independent Director
- 127.95K
- Edward T. Mathers
- Independent Director
- 110.45K
- Dominick C. Colangelo
- Independent Director
- 120.45K
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025